I do agree that the one problem with CYDY is Nader over promising, it was wrong for him to create the "golden quarter". However we know the FDA and the clinical trial sites are not under Nader's control so to blindly put an exact date on a milestone under those conditions is foolish - i would certainly like for Nader's confidence to be true but the future has not changed because of one date. Pro 140 works, trial sites are enrolling, patients are being injected, their lives are much better, the market is in the billions and growing, BP has patents that are running out, BP likes treatments better than cures, CYDY has access to funding to go through all clinical trials, and we are able to buy this for $.60 a share. What more do you need?
The only reasons for the valuation not being where we think it should be is the market we are listed on, lack of publicity, the sea of other biotechs with other promising products that might be more appealing, fickle traders who want to jump in just before the spike and sell for a quick profit and a slow moving FDA.
We can cherry pick facts all we want, but the story is the same, CYDY is still working toward the same thing we want them to. it will get there when it gets there. Mar 31 is just a day.
News 
Market Data 
Discover 
